Actively Recruiting
The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery
Led by Beijing Tiantan Hospital · Updated on 2026-03-06
100
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy. It is reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process.If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Local infiltration anesthesia at the incision site is one of the simplest, safest, and most effective methods for preventing postoperative incision pain. Liposomal bupivacaine(LB) is a novel, long-acting, sustained-release amide-type local anesthetic, providing localized analgesic effects for up to 72 hours. Some researchers have reported the analgesic effects of LB VS traditional local anesthetics infiltration, but the current research results are highly heterogeneous. More prospective studies are needed to evaluate whether LB infiltration is superior to the traditional local anesthetics for the management of postoperative pain. The investigators designed this study to compare the analgesic effect of using LB plus bupivacaine for local infiltration with bupivacaine along for patients after VATS.
CONDITIONS
Official Title
The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients scheduled for elective video-assisted thoracoscopic lobectomy or wedge resection under general anesthesia
- Ages 18 to 64 years old
- American Society of Anesthesiologists (ASA) physical status of I-III
- Glasgow Coma Scale (GCS) score of 15
- Ability to understand the trial and provide informed consent
You will not qualify if you...
- History of chronic pain syndrome of any cause
- Heart conduction block (sinus block or atrioventricular block)
- Unstable coronary artery disease
- Gastric ulcer or gastric bleeding
- Diabetes treated with insulin
- Coagulation dysfunction or taking oral anticoagulants not stopped before surgery
- Abnormal liver function (ALT/AST > 2x upper limit of normal or total bilirubin ≥ 1.5x upper limit)
- Renal impairment or dialysis within 28 days before surgery
- History of diagnosed mental illness or current psychotropic medication use
- Excessive alcohol or drug abuse, chronic opioid use, or use of sedative/analgesic drugs before surgery
- Pregnancy or breastfeeding
- Extreme body mass index (BMI < 15 or > 35)
- Participation in another interventional trial affecting this study
- Allergy to local anesthetics or study drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China, 100070
Actively Recruiting
Research Team
F
Fang Luo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here